Document is current
Any future updates will be listed below
-
Authors
Edwards, Lucy
Parker, Geoff J. M.
Waterton, John C.
Tibiletti, Marta
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative 2 (116106)
- License Information
-
More Information
Article History
Received: 20 December 2024
Revised: 11 April 2025
Accepted: 23 April 2025
First Online: 16 May 2025
Declarations
:
: John Waterton holds stock in Quantitative Imaging Ltd and is a director of, and has received compensation from, Bioxydyn Ltd, a for-profit company engaged in the discovery and development of MR biomarkers and the provision of imaging biomarker services. Marta Tibiletti holds stock in Quantitative Imaging Ltd and is an employee of, and has received compensation from, Bioxydyn Ltd, a for-profit company engaged in the discovery and development of MR biomarkers and the provision of imaging biomarker services. Lucy Edwards is an employee of, and has received compensation from, Bioxydyn Ltd, a for-profit company engaged in the discovery and development of MR biomarkers and the provision of imaging biomarker services. Geoffrey Parker holds stock in and is a director of Quantitative Imaging Ltd, Bioxydyn Ltd, and Queen Square Analytics Ltd, each of which are for-profit companies engaged in the discovery and development of imaging biomarkers and the provision of imaging biomarker services. He has also received compensation from Bioxydyn Ltd.
: This article is a systematic review and meta-analysis of previously published studies and does not involve any new studies with human participants or animals performed by the authors. As such, ethical approval and informed consent were not required.
